Navigation Links
CMSI produces Low cost Anti-retroviral drugs in India

Comprehensive Medical Services India (CMSI) has produced two Anti-retrovirals which can be used in the treatment of HIV/AIDS. The two drugs Nevirapine and Zidovudine is produced by CMSI in its // manufacturing unit in Chennai, India. These two drugs were officially released by Sebastian Ouseperamppil, Director-general, Catholic Health Association. A new microbiology department which could maintain the quality control and Research facilities was dedicated to this manufacturing unit.

The two drugs, Nevirapine and Zidovudine, manufactured by the Essential Drug project of the CMSI, are now available at “reasonable” rates. The organization will soon make available the other components of the ARV tri-drug therapy: Lamivudine, Efaravenz and Combinations of Lamivudine, Stavudine and Nevirapine in various strengths, said CMSI executive trustee-director Moses P. Manohar. Jane Masiga, from the Mission for Essential Drugs and Supplies, Nairobi, Kenya, received the first consignment of Zidovudine capsules from Bimal Charles, Epidemiologist, Center for Disease Control.

Dr. Charles of Center for Disease Control said that the company should maintain the quality of the drugs without compromising on the cost of the drug by maintaining strict quality control measures. He said that the AIDS drugs which was very expensive and is less affordable by economically weaker section has become cheaper and could be affordably brought by the patients.
'"/>




Page: 1

Related medicine news :

1. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
2. Anti-retroviral drug conserving trial halted
3. One Lakh HIV Patients to get Free Anti-retroviral Drugs by 2007
4. Mental Illness Reversed with Anti-retrovirals in HIV Cases
5. Cancer drugs in development nearly doubled since 1995
6. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
7. African HIV strains more resistant to anti HIV drugs
8. Right drugs drastically cut stroke risk
9. Relating heart protection and antihypertensive drugs
10. Enzyme may be target for obesity drugs
11. New HIV cases resist drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... , ... January 19, 2017 , ... ... a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus ... condensed version of the clinic’s leading recovery program. , “We know it’s ...
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. is ... modern CTMS workflow designed to seamlessly integrate and streamline the way researchers prepare ... single page, maximizing usability and improving efficiency significantly for users – a first ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... 19, 2017 , ... Rountree Brady Insurance Agency, a Savannah ... eastern Georgia, is embarking on a charity effort to raise awareness and gather ... every year than anything else, yet risk factors associated with heart disease are ...
(Date:1/19/2017)... ... 2017 , ... Attorney Robert “RC” Pate , founder of The Law ... Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. ... the effect of the critical funding gap for research into pediatric cancer research. From ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... 18, 2017   Synthetic Biologics, Inc. ... therapeutics designed to preserve the microbiome to protect ... plans to initiate a Phase 2b/3 adaptive pivotal ... lovastatin lactone designed to reduce methane production by ... gut to treat the underlying cause of irritable ...
(Date:1/18/2017)... PAUL, Minn. , Jan. 18, 2017 /PRNewswire-USNewswire/ ... developer of medical devices using neuroblocking technology to ... today announced the pricing of an underwritten public ... million, prior to deducting underwriting discounts and commissions ... The offering is comprised of Class A Units, ...
Breaking Medicine Technology: